The effect of changing of conventional antihypertensive therapy to a triple fixed combination therapy with rosuvastatin in high cardiovascular risk patients

Background. The low efficiency of recommended therapy for reducing cardiovascular risk (CV) in patients with arterial hypertension even with an effective blood pressure decrease is often due to the persistence of high blood cholesterol and arterial stiffness. Among the effective ways to achieve the goal of therapy is considered the changing to a single-pill combinations (SPCs) of two antihypertensive drugs and statin. Aim. To assess influence of fixed combination consisted of amlodipine, lisinopril and rosuvastatin to the dynamic of lipid spectrum, blood pressure level and elastic properties of arteries in patients with arterial hypertension and high risk of cardio-vascular complications being transferred from their preceding antihypertensive therapy. Materials and methods. 113 patients with atherosclerosis of brachiocephalic arteries (BCA) receiving antihypertensive and partially taking statins therapy were assessed cholesterol, low-density lipoprotein cholesterol (LDL-C), peripheral and central blood pressure, carotid-femoral pulse wave velocity (PWV) initially and after 12 months of taking amlodipine + lisinopril + rosuvastatin (A+L+R) SPCs. Results. The administration ofA+L+R SPCs for 12 months was associated with an increasing of number of patients with the achieved target blood pressure <140/90 mm Hg from 68% to 100%, the target level of LDL-C <2.5 mmol/l from 7% to 88.5%, the PWV <10 m/s from 33% to 67%. In spite of the initial class antihypertensive therapy (the renin-angiotensin-aldosterone system blockers (RAAS) (n = 52), the RASS + diuretic (n = 10), the RAAS + calcium antagonist (CA) (n = 47) the administration of A+L+R SPCs led to a reduction of both central and peripheral blood pressure, as well as PWV. Conclusions: Changing of monotherapy or combined therapy of RAAS, CA, or diuretics to the therapy of A+L+R SPCs in high CV risk patients even with partially normal blood pressure allowed to achieve the target blood pressure, LDL-C level, and PWV in most patients effectively and safely.

сердечно-сосудистый риск, фиксированная комбинация, ХС липопротеидов низкой плотности, центральное АД, скорость пульсовой волны, cardiovascular risk, fixed-dose combination, low-density lipoprotein cholesterol, central arterial pressure, pulse wave velocity

1. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular diseaseThe Task Force on ACE-inhibitors of the European Society of Cardiology. European Heart Journal. 2004; 25(16): 1454-70. DОI: 10.1016/j.ehj.2004.06.003

2. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996; 275(19): 1507-13. PMID: 8622227

3. Brilla C.G., Matsubara L., Weber K.T. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension. 1996; 28 (2): 269-75.

4. Brilla C.G., Funck R.C., Rupp H. Lisinopril-mediated regression ofmyo-cardial fibrosis in patients with hypertensive heart disease. Circulation. 2000; 102 (12): 1388-93.

5. Sun Y., Ratajska A., Weber K.T. Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med. 1995; 126 (1): 95-101.

6. The CAFE Investigators. Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006; 113 (9): 1213-25. DОI: 10.1161/CIRCU-LATIONAHA. 105.595496

7. Marin F., Pascual D.A., Roldan V., Arribas J.M., Ahumada M., Tornel P.L. et al. Statins and Postoperative Risk of Atrial Fibrillation Following Coronary Artery Bypass Grafting. The American Journal of Cardiology. 2006; 97 (1): 55-60. DОI: 10.1016/j.amjcard. 2005.07.124

8. Драпкина О.М., Палаткина Л.О., Зятенкова Е.В. Плейотропные эффекты статинов. Влияние на жесткость сосудов. Врач. 2012; (9): 5-9. [Drapkina О. M., Palatkina L. O., Zyatenkova E. V. Pleiotropic effects of statins. Action on vascular rigidity. The doctor. 2012; 9: 5-9.]

9. Ежов М.В., Сергиенко И.В., Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., Бажан С.С. et al. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017; (3): 5-22.

10. Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В., Архипов М.В., Барбараш О.Л., Галявич А.С. et al. Клинические рекомендации Диагностика и лечение АГ. Кардиологический вестник. 2015; X(1): 3-30.

11. Berger J.S., Jordan C.O., Lloyd-Jones D., Blumenthal R.S. Скрининг сердечно-сосудистого риска у бессимптомных пациентов. Рациональная фармакотерапия в кардиологии. 2010; 6 (3): 381-90.

12. Карпов Ю.А. Исследование ТРИУМВИРАТ: снижение риска развития сердечно-сосудистых осложнений у больных АГ с помощью трехкомпонентной комбинации антигипертензивных и липидснижающих препаратов. Кардиология. 2015; 55 (9): 10-5.

13. Bress A.P., Tanner R.M., Hess R., Colantonio L.D., Shimbo D., Muntner P. Generalizability of SPRINT Results to the U. S. Adult Population. Journal of the American College of Cardiology. 2016; 67(5): 463-72. DOI: 10.1016/j.jacc. 2015.10.037

14. Whelton P.K., Carey R.M., Aronow W.S., Casey D.E., Collins K.J., Dennison Himmelfarb C., et al. 2017 ACC/AHA /AAPA /ABC /ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.Journal of the American College of Cardiology [Internet]. 2017 [cited 2018]; DOI: 10.1016/j.jacc. 2017.11.006

15. Бланкова З.Н., Асланян Н.С. Влияние комбинированной терапии на состояние сосудистой стенки у больных высокого сердечно-сосудистого риска. Системные Гипертензии. 2017; 14(2): 51-5. [Blankova Z. N., Aslanyan N. S. The effect of combined therapyon the properties of the vessel wall in patients at high risk of cardiovascularcomplications. Systemic Hypertension. 2017; 14(2): 51-5].

16. Глезер М.Г., Выгодин В.А., Авакян А.А., Прокофьева Е.Б. Результаты российской Программы ЭКСПЕРТ (Постмаркетинговое наблюдение за ЭффеКтивностью и влиянием ПрЕпарата ЭкватоР на качество жизни у пациентов с АГ в амбулаТорной практике). Кардиология. 2014; 54 (3): 15-22.

17. Yusuf S., Bosch J., Dagenais G., Zhu J., Xavier D., Liu L. et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine. 2016; 374(21): 2021-31. DOI: 10.1056/NEJMoa1600176